Clinton is joined by Anthony Flynn, Director of Health Knowledge & Translation at Asthma Australia, to discuss the changes that took effect on 1 September 2024, when over 70 asthma inhalers were added to the Pharmaceutical Benefits Scheme (PBS) with a 60-day prescription option.

This follows advice from the independent Pharmaceutical Benefits Advisory Committee (PBAC), which deemed it clinically safe for eligible patients.

Prescribers now have the discretion to choose between 30 or 60-day prescriptions based on their professional judgement.

Download this podcast here